A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan

X Cun, S Ruan, J Chen, L Zhang, J Li, Q He, H Gao - Acta biomaterialia, 2016 - Elsevier
Although development of nanomedicines has been a promising direction in tumor treatment,
the therapeutic outcome of current nanomedicines is unsatisfying, partly because of the poor …
被引用次数：117 相关文章

A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan.

X Cun, S Ruan, J Chen, L Zhang, J Li, Q He… - Acta …, 2015 - europepmc.org
Although development of nanomedicines has been a promising direction in tumor treatment,
the therapeutic outcome of current nanomedicines is unsatisfying, partly because of the poor …

[引用][C] A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan

X Cun, S Ruan, J Chen, L Zhang, J Li, Q He, H Gao - Acta Biomaterialia, 2016 - cir.nii.ac.jp
A dual strategy to improve the penetration and treatment of breast cancer by combining
shrinking nanoparticles with collagen depletion by losartan | CiNii Research CiNii 国立情報学 …

A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan

X Cun, S Ruan, J Chen, L Zhang, J Li, Q He, H Gao - Acta Biomaterialia, 2016 - infona.pl
Although development of nanomedicines has been a promising direction in tumor treatment,
the therapeutic outcome of current nanomedicines is unsatisfying, partly because of the poor …

A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan

X Cun, S Ruan, J Chen, L Zhang, J Li… - Acta …, 2016 - pubmed.ncbi.nlm.nih.gov
Although development of nanomedicines has been a promising direction in tumor treatment,
the therapeutic outcome of current nanomedicines is unsatisfying, partly because of the poor …